GCIScancell reports strong clinical data for cancer vaccine in FY24, poised for key milestones ahead
() , a developer of immunotherapies for the treatment of cancer, announced its final results for the year ended April 30, 2024 plus a post-period update.
Scancell's lead cancer vaccine SCIB1 saw positive data from the first stage of its Phase 2 SCOPE trial for advanced melanoma, with an objective response rate exceeding the 70% target set for continuation of the study. The trial also added an additional cohort for iSCIB1+, a next-gen variant suitable for a broader patient population.
Full cohort data with SCIB1 and iSCIB1+ is expected in Q4 2024 and H1 2025 respectively. Additionally, a Phase 2/3 registration study in advanced melanoma is planned for 2025, supported by strategic guidance from key stakeholders.
Scancell's other main asset, the Modi-1 vaccine, completed dose escalation and safety cohorts of the Phase 1/2 'ModiFY' study, and continues in the expansion cohorts. Early data showed good safety and ability to induce stable disease for long periods. A cohort in advanced RCC patients evaluating Modi-1 was approved and added to the ModiFY study, with an early clinical read-out expected in H1 2025.
Financially, reported an operating loss for the 12-month period to April 30, 2024 of £18.3m, an increase from last year due to higher investment in its vaccine and antibody platforms. Financing in late 2023 raised gross proceeds of £11.9m, boosting the group's cash balance to £14.8m as of April 30, 2024, with cash runway through to calendar Q3 2025 beyond expected near-term clinical milestones.
View from Vox
Scancell reports significant clinical progress across its portfolio in the rapidly growing sector of cancer immunotherapy, with both lead assets set for major milestones over the next 18 months. Scancell's flagship SCIB1 for advanced melanoma saw 11 out of 13 patients achieving at least a partial response in the first stage of its Phase 2 study, exceeding the study's target.
Simultaneously, the next-gen version of the vaccine, iSCIB1+, was added as an additional cohort. The programme promises to become the new standard for first-line treatment of unresectable melanoma and one of the world's first off-the-shelf cancer vaccines - a major potential milestone and value inflection point for Scancell. Investors can look forward to a pivotal Phase 2/3 registration study in 2025, supported by guidance from stakeholders.
Scancell's other lead candidate Modi-1 likewise saw substantial development during the period, including the addition of a RCC cohort with checkpoint inhibitors. For its remaining assets, the group continued to seek partners, having signed post-period an agreement with a major biotech to exclusively evaluate an antibody in 's GlyMab portfolio, receiving $1m in July 2024.
The financing in late 2023 raised a total of £11.9m, leaving the company funded through Q2 2025, beyond the data readout from SCIB1's Phase 2 SCOPE trial and early data from the new renal cohort of the ModiFY trials.
Follow News & Updates from Scancell:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.